News & Updates

Show Multimedia Only

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025 by

The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

05 Aug 2025

In the treatment of patients with aspiration pneumonia, ampicillin–sulbactam helps reduce in-hospital mortality and prevent Clostridioides difficile infection compared with cephalosporins, according to a study from Japan.

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

05 Aug 2025

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID

03 Aug 2025

For individuals with long COVID, treatment with nirmatrelvir plus ritonavir does not appear to yield improvements in health outcomes when compared with ritonavir alone, according to a phase II study.

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID

03 Aug 2025

Handheld device-questionnaire combo improves COPD diagnosis

25 Jul 2025 by

In patients with suspected chronic obstructive pulmonary disease (COPD), the combination of FEV1/FEV6 and COPD diagnostic questionnaire (CDQ) demonstrates the highest diagnostic accuracy as well as cost-effectiveness in detecting at-risk individuals, according to a Taiwan study.

Handheld device-questionnaire combo improves COPD diagnosis

25 Jul 2025

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

25 Jul 2025

Treatment with nerandomilast helps preserve lung function in patients with idiopathic pulmonary fibrosis, as shown in the phase III FIBRONEER-IPF trial.

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

25 Jul 2025

Predictive model identifies women with COPD in need of palliative care

23 Jul 2025 by

A newly developed prediction model has demonstrated robust performance in recognizing women with chronic obstructive pulmonary disease (COPD) who might benefit from proactive palliative care. However, external validation is warranted.

Predictive model identifies women with COPD in need of palliative care

23 Jul 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

New drug applications approved by US FDA as of 1-15 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

Nirsevimab efficacy against RSV-LRTI hospitalization sustained at 6 months

23 Jul 2025 by

Updated results from the phase IIIB HARMONIE trial demonstrate sustained efficacy of the long-acting monoclonal antibody nirsevimab against respiratory syncytial virus-associated lower respiratory tract infection (RSV-LRTI) hospitalization through day 181 post-dose.

Nirsevimab efficacy against RSV-LRTI hospitalization sustained at 6 months

23 Jul 2025

Original New Drug Application Approvals by US FDA (16-30 June 2025)

23 Jul 2025

New drug applications approved by US FDA as of 16-30 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2025)

23 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

Aspiration pneumonia outcomes better with ampicillin–sulbactam vs cephalosporins

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID

Nirmatrelvir–ritonavir combo not better than ritonavir alone in adults with long COVID

Handheld device-questionnaire combo improves COPD diagnosis

Handheld device-questionnaire combo improves COPD diagnosis

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

Nerandomilast may slow lung function decline in idiopathic pulmonary fibrosis

Predictive model identifies women with COPD in need of palliative care

Predictive model identifies women with COPD in need of palliative care

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

Nirsevimab efficacy against RSV-LRTI hospitalization sustained at 6 months

Nirsevimab efficacy against RSV-LRTI hospitalization sustained at 6 months

Original New Drug Application Approvals by US FDA (16-30 June 2025)

Original New Drug Application Approvals by US FDA (16-30 June 2025)